Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.8B
131M shares
52-week range
$11.41 – $23.44
21% from low
Sector
SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC
Exchange
NASDAQ
CS
P/S (TTM)
0.5
EV / FCF (TTM)
29.8
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
www.surgerypartners.comNo one on the platform currently holds SGRY.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 262,000 | $5.7M |
| Bridgewater Associatesas of 2024-06-30 | 18,938 | $450.5K |
No one on the platform has traded SGRY yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 6.2% | 12.2% | ||||
| Profit Margin % | -2.4% | -2.7% | -3.9% | |||
| Free Cash Flow Margin % | 5.9% | 4.9% | 5.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +0.0% on the P/E track.
At today's price, your expected annual return is +4.7% on the P/E track.
At today's price, your expected annual return is +8.8% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.4B | +4.1% | $0.46 | $0.40–$0.50 | 30.4× | 7 |
| 2027 | $3.5B | +2.5% | $0.54 | $0.42–$0.66 | 25.8× | 5 |
| 2028 | $3.7B | +4.9% | $0.68 | $-1.90–$3.25 | 20.5× | 2 |
| 2029 | $3.6B | -2.3% | $0.56 | $0.55–$0.56 | 24.9× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | $0.06 | $0.10 | +72.6% |
| 2026-05-05 | $-0.15 | $-0.03 | +80.0% |
| 2026-03-02 | $0.31 | $0.12 | -61.3% |
| 2025-11-10 | $0.19 | $0.13 | -31.6% |
| 2025-08-05 | $0.16 | $0.17 | +6.3% |
| 2025-05-12 | $0.08 | $0.04 | -50.0% |
| 2025-03-03 | $0.38 | $0.44 | +15.8% |
| 2024-11-12 | $0.25 |
| $0.19 |
| -24.0% |
| $5.6B |
| — |
| HTFLHeartflow, Inc. Common Stock | $48.30 | -0.06% | $4.2B | — |
| IDYAIDEAYA Biosciences, Inc. | $37.73 | +0.19% | $3.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SGRY Insider purchase: https://filingtracker.ai/filing/1638833/0001638833-26-000079
View on StockTwits ↗$SGRY Did buy shares today, price target next year is $22
View on StockTwits ↗
SGRY Q2 2026 Earnings Summary $SGRY https://stocktwits.com/news/earnings/ai summaries/sgry-q2-2026-earnings-summary/cZojDrWRJfT
View on StockTwits ↗
Midday Fly By: Intel announces $15B offering, Meta unveils Muse Glimmer - $SGRY - https://thefly.com/SGRY
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-10-surgery-partners-inc-stock/ $SGRY Surgery Partners Earnings Transcript
View on StockTwits ↗
$SGRY (+2.5% pre) Surgery Partners Q2 revenue beats on growth in same-facility segment https://ooc.bz/l/110602
View on StockTwits ↗
$SGRY Positive (78%): shares face upward price pressure because reported revenue and non-GAAP EPS above consensus can prompt higher earnings estimates, although a full-year revenue outlook close to existing expectations caps the potential revaluation. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/b05d5a9056454a38?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗
$SGRY Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 down -500.00% YoY • Reported revenue of $848.9M up 2.75% YoY • Surgery Partners reaffirmed its full year 2026 revenue guidance in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture.
View on StockTwits ↗
$SGRY reported YoY revenue growth for Q2, 4.50% in Q1. http://www.estimize.com/intro/sgry?chart=historical&metric_name=revenue&utm_conten
View on StockTwits ↗Wall St is expecting 0.06 EPS for $SGRY Q2 [Reporting 08/10 BMO] http://www.estimize.com/intro/sgry?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
Surgery Partners shares rose after the company announced it had placed binding signature pages into escrow for the sale of its interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The two Idaho facilities were valued at approximately $1.15 billion, with Surgery Partners expected to receive about $795 million in total consideration. Investors welcomed the transaction as a major balance-sheet catalyst, sending the stock sharply higher during the session. The company also reaffirmed its 2026 outlook, maintaining revenue guidance of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the impact of the sale. CEO Eric Evans described the deal as part of Surgery Partners’ portfolio optimization strategy, allowing the company to redeploy capital and management focus toward its ambulatory surgery center business, where it sees stronger long-term growth opportunities. $SGRY $SPX
View on StockTwits ↗
$SGRY continues to optimize its portfolio with the sale of its ownership interests in Idaho Falls facilities to Intermountain Health. The transaction supports the company’s strategy of refining its asset base while maintaining its financial outlook. Portfolio adjustments like this can help improve capital allocation and focus resources on higher-value opportunities. Execution and future growth initiatives remain the key areas to watch.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.